Dr. Reddy’s Laboratories announced the first-to-market launch of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, a generic equivalent of Ciprodex® Otic Suspension (Alcon Laboratories).
The otic suspension combines ciprofloxacin, a fluoroquinolone antibacterial, with dexamethasone, a corticosteroid, for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below:
- Acute otitis media in pediatric patients aged ≥6 months with tympanostomy tubes due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa.
- Acute otitis externa in patients aged ≥6 months due to Staphylococcus aureus and Pseudomonas aeruginosa.
The product is supplied as 7.5mL of suspension in a 10mL bottle.
For more information visit drreddys.com.
Dr. Reddy’s Laboratories announces the first-to-market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the US market. https://www.businesswire.com/news/home/20200810005834/en/Dr.-Reddys-Laboratories-announces-First-to-Market-launch-generic. Accessed August 11, 2020.
This article originally appeared on MPR